These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 8616082)

  • 1. Analysis of p53 and mdm-2 expression in 18 patients with Sézary syndrome.
    Marks DI; Vonderheid EC; Kurz BW; Bigler RD; Sinha K; Morgan DA; Sukman A; Nowell PC; Haines DS
    Br J Haematol; 1996 Mar; 92(4):890-9. PubMed ID: 8616082
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular pathology of primary and metastatic ductal pancreatic lesions: analyses of mutations and expression of the p53, mdm-2, and p21/WAF-1 genes in sporadic and familial lesions.
    Ruggeri BA; Huang L; Berger D; Chang H; Klein-Szanto AJ; Goodrow T; Wood M; Obara T; Heath CW; Lynch H
    Cancer; 1997 Feb; 79(4):700-16. PubMed ID: 9024708
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of the p53 and MDM-2 gene in acute myeloid leukemia.
    Seliger B; Papadileris S; Vogel D; Hess G; Brendel C; Störkel S; Ortel J; Kolbe K; Huber C; Huhn D; Neubauer A
    Eur J Haematol; 1996 Sep; 57(3):230-40. PubMed ID: 8898928
    [TBL] [Abstract][Full Text] [Related]  

  • 4. mdm-2 expression correlates with wild-type p53 status in esophageal adenocarcinoma.
    Soslow RA; Altorki NK; Yang G; Xie D; Yang CS
    Mod Pathol; 1999 Jun; 12(6):580-6. PubMed ID: 10392633
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunohistochemical and molecular evaluation of the mdm-2 gene product in bronchogenic carcinoma.
    Gorgoulis VG; Rassidakis GZ; Karameris AM; Papastamatiou H; Trigidou R; Veslemes M; Rassidakis AN; Kittas C
    Mod Pathol; 1996 May; 9(5):544-54. PubMed ID: 8733770
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MDM-2 oncoprotein overexpression, p53 gene mutation, and VEGF up-regulation in angiosarcomas.
    Zietz C; Rössle M; Haas C; Sendelhofert A; Hirschmann A; Stürzl M; Löhrs U
    Am J Pathol; 1998 Nov; 153(5):1425-33. PubMed ID: 9811333
    [TBL] [Abstract][Full Text] [Related]  

  • 7. p53 allele deletion and protein accumulation occurs in the absence of p53 gene mutation in T-prolymphocytic leukaemia and Sezary syndrome.
    Brito-Babapulle V; Hamoudi R; Matutes E; Watson S; Kaczmarek P; Maljaie H; Catovsky D
    Br J Haematol; 2000 Jul; 110(1):180-7. PubMed ID: 10930996
    [TBL] [Abstract][Full Text] [Related]  

  • 8. p53 mutations and MDM-2 amplification in renal cell cancers.
    Imai Y; Strohmeyer TG; Fleischhacker M; Slamon DJ; Koeffler HP
    Mod Pathol; 1994 Sep; 7(7):766-70. PubMed ID: 7824511
    [TBL] [Abstract][Full Text] [Related]  

  • 9. P53 expression in Reed-Sternberg cells does not correlate with gene mutations in Hodgkin's disease.
    Elenitoba-Johnson KS; Medeiros LJ; Khorsand J; King TC
    Am J Clin Pathol; 1996 Dec; 106(6):728-38. PubMed ID: 8980348
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The tumour suppressor p53 is frequently nonfunctional in Sézary syndrome.
    Lamprecht B; Kreher S; Möbs M; Sterry W; Dörken B; Janz M; Assaf C; Mathas S
    Br J Dermatol; 2012 Aug; 167(2):240-6. PubMed ID: 22384858
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Altered expression of p53 and mdm-2 proteins at diagnosis is associated with early treatment failure in childhood acute lymphoblastic leukemia.
    Marks DI; Kurz BW; Link MP; Ng E; Shuster JJ; Lauer SJ; Carroll D; Brodsky I; Haines DS
    J Clin Oncol; 1997 Mar; 15(3):1158-62. PubMed ID: 9060559
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunohistochemical detection of p53 in melanomas with rare p53 gene mutations is associated with mdm-2 overexpression.
    Poremba C; Yandell DW; Metze D; Kamanabrou D; Böcker W; Dockhorn-Dworniczak B
    Oncol Res; 1995; 7(7-8):331-9. PubMed ID: 8747596
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The p53 and mdm-2 genes in human testicular germ-cell tumors.
    Riou G; Barrois M; Prost S; Terrier MJ; Theodore C; Levine AJ
    Mol Carcinog; 1995 Mar; 12(3):124-31. PubMed ID: 7893365
    [TBL] [Abstract][Full Text] [Related]  

  • 14. P53 and mdm-2: interactions between tumor suppressor gene and oncogene products.
    Perry ME; Levine AJ
    Mt Sinai J Med; 1994 Sep; 61(4):291-9. PubMed ID: 7969222
    [TBL] [Abstract][Full Text] [Related]  

  • 15. p21WAF1/CIP1 and MDM2 expression in non-Hodgkin's lymphoma and their relationship to p53 status: a p53+, MDM2-, p21-immunophenotype associated with missense p53 mutations.
    Villuendas R; Pezzella F; Gatter K; Algara P; Sánchez-Beato M; Martínez P; Martínez JC; Muñoz K; García P; Sánchez L; Kocialkowsky S; Campo E; Orradre JL; Piris MA
    J Pathol; 1997 Jan; 181(1):51-61. PubMed ID: 9072003
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Decreased BRCA1 expression levels may arrest the cell cycle through activation of p53 checkpoint in human sporadic breast tumors.
    Sourvinos G; Spandidos DA
    Biochem Biophys Res Commun; 1998 Apr; 245(1):75-80. PubMed ID: 9535786
    [TBL] [Abstract][Full Text] [Related]  

  • 17. P53, MDM-2, BAX and BCL-2 and drug resistance in chronic lymphocytic leukemia.
    Johnston JB; Daeninck P; Verburg L; Lee K; Williams G; Israels LG; Mowat MR; Begleiter A
    Leuk Lymphoma; 1997 Aug; 26(5-6):435-49. PubMed ID: 9389352
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictive value of p53, mdm-2, p21, and mib-1 for chemotherapy response in advanced breast cancer.
    Sjöström J; Blomqvist C; Heikkilä P; Boguslawski KV; Räisänen-Sokolowski A; Bengtsson NO; Mjaaland I; Malmström P; Ostenstadt B; Bergh J; Wist E; Valvere V; Saksela E
    Clin Cancer Res; 2000 Aug; 6(8):3103-10. PubMed ID: 10955790
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Amplification of the mdm-2 gene and p53 abnormalities in uterine sarcomas.
    Seki A; Kodama J; Miyagi Y; Kamimura S; Yoshinouchi M; Kudo T
    Int J Cancer; 1997 Sep; 73(1):33-7. PubMed ID: 9334806
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Elevated levels of MDM-2 and p53 expression are associated with high grade non-Hodgkin's lymphomas.
    Finnegan MC; Goepel JR; Royds J; Hancock BW; Goyns MH
    Cancer Lett; 1994 Nov; 86(2):215-21. PubMed ID: 7982210
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.